Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy Article (Web of Science) Early Access (Web of Science)

Industry Collaboration

cited authors

  • Sliheet, Elyssa; Robinson, Molly; Morand, Susan; Choucair, Khalil; Willoughby, David; Stanbery, Laura; Aaron, Phylicia; Bognar, Ernest; Nemunaitis, John

publication date

  • November 16, 2021


published in